Corcept Therapeutics Shareholder Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy CORT?
Source: Globenewswire
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: During the Class Period from 2024 to 2025, Corcept is accused of failing to disclose serious FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, leading to investor misconceptions about the company's prospects.
- Stock Price Crash: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market disappointment in the company's outlook.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, potentially impacting investors' future decision-making based on inaccurate perceptions of the company's operational status.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 43.680
Low
50.00
Averages
91.00
High
121.00
Current: 43.680
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds shareholders of Corcept Therapeutics that the critical lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their loss claims before this date to protect their rights.
- Loss Scope: The lawsuit pertains to investor losses incurred between October 31, 2024, and December 30, 2025, with allegations that the company failed to disclose significant communications with the FDA, leading shareholders to misunderstand the approval potential of its drug candidate, relacorilant.
- Information Disparity Allegations: The complaint claims that Corcept publicly emphasized the potential approval of relacorilant while failing to disclose management's expectations of failure, creating a
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant due to insufficient evidence of effectiveness, resulting in a 50.42% drop in stock price to $34.80, highlighting serious concerns about the adequacy of its clinical development program.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock price plummeted by $35.40, reflecting a pessimistic market sentiment regarding the company's future prospects and severely undermining investor confidence in its drug development capabilities, which could impact future financing and partnership opportunities.
- Class Action Initiated: Investors have filed a class action lawsuit alleging that Corcept made materially false and misleading statements during the Class Period from October 31, 2024, to December 30, 2025, failing to disclose the FDA's significant concerns about the drug's effectiveness assessment, potentially leading to investor losses.
- Legal Deadline: Investors must file a motion by April 21, 2026, to request appointment as lead plaintiff in this class action, indicating the urgency of the case and its potential implications for affected investors, which may trigger further legal and financial liabilities.
See More
Corcept Therapeutics Faces Class Action for Disclosure Failures
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for failing to disclose material information during the period from October 31, 2024, to December 30, 2025, with investors required to file lead plaintiff applications by April 21, 2026, to seek recovery for economic losses.
- FDA Response Letter: During the class period, Corcept assured investors of a high likelihood of FDA approval for its new drug application; however, on December 31, 2025, it received a Complete Response Letter from the FDA, necessitating additional evidence of effectiveness, which led to a significant drop in stock price.
- Stock Price Impact: Following the FDA's response, Corcept's stock plummeted by 50.4%, from $70.20 on December 30, 2025, to $34.80, representing a loss of $35.40 per share, indicating severe market pessimism regarding the company's future prospects.
- Legal Consultation Opportunity: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact Kahn Swick & Foti for a free consultation, assisting them in navigating the lawsuit process.
See More
Corcept Therapeutics Faces Class Action Lawsuit for Securities Fraud
- Class Action Initiated: Pomerantz LLP has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by April 21, 2026.
- FDA Complete Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, requiring additional evidence of effectiveness, which poses significant compliance challenges for the company.
- Stock Price Plunge: Following the FDA's negative feedback, Corcept's stock price plummeted by $35.40, or 50.4%, closing at $34.80 per share on December 31, 2025, severely impacting investor confidence and market performance.
- Legal Firm Background: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, emphasizes its commitment to fighting for victims of securities fraud and corporate misconduct, highlighting the potential legal ramifications for Corcept in this case.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the support for its drug relacorilant's New Drug Application (NDA) to the FDA, despite the agency expressing concerns about the adequacy of clinical evidence, which exposed investors to significant risk of loss.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this legal domain.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging affected investors to submit their losses before this date to participate in the lawsuit.
- Loss Scope: The lawsuit pertains to investor losses incurred between October 31, 2024, and December 30, 2025, with allegations that the company failed to disclose critical communications with the FDA, leading to misleading expectations regarding the potential approval of its lead drug candidate, relacorilant.
- Information Asymmetry: The complaint alleges that Corcept's management was privately informed of potential failure in FDA communications but publicly conveyed an optimistic outlook to investors, creating a significant information gap that may have led to misguided investment decisions.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, aiming to enhance oversight and accountability for corporate misconduct.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds shareholders of Corcept Therapeutics that the critical lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their loss claims before this date to protect their rights.
- Loss Scope: The lawsuit pertains to investor losses incurred between October 31, 2024, and December 30, 2025, with allegations that the company failed to disclose significant communications with the FDA, leading shareholders to misunderstand the approval potential of its drug candidate, relacorilant.
- Information Disparity Allegations: The complaint claims that Corcept publicly emphasized the potential approval of relacorilant while failing to disclose management's expectations of failure, creating a
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant due to insufficient evidence of effectiveness, resulting in a 50.42% drop in stock price to $34.80, highlighting serious concerns about the adequacy of its clinical development program.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock price plummeted by $35.40, reflecting a pessimistic market sentiment regarding the company's future prospects and severely undermining investor confidence in its drug development capabilities, which could impact future financing and partnership opportunities.
- Class Action Initiated: Investors have filed a class action lawsuit alleging that Corcept made materially false and misleading statements during the Class Period from October 31, 2024, to December 30, 2025, failing to disclose the FDA's significant concerns about the drug's effectiveness assessment, potentially leading to investor losses.
- Legal Deadline: Investors must file a motion by April 21, 2026, to request appointment as lead plaintiff in this class action, indicating the urgency of the case and its potential implications for affected investors, which may trigger further legal and financial liabilities.
See More
Corcept Therapeutics Faces Class Action for Disclosure Failures
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for failing to disclose material information during the period from October 31, 2024, to December 30, 2025, with investors required to file lead plaintiff applications by April 21, 2026, to seek recovery for economic losses.
- FDA Response Letter: During the class period, Corcept assured investors of a high likelihood of FDA approval for its new drug application; however, on December 31, 2025, it received a Complete Response Letter from the FDA, necessitating additional evidence of effectiveness, which led to a significant drop in stock price.
- Stock Price Impact: Following the FDA's response, Corcept's stock plummeted by 50.4%, from $70.20 on December 30, 2025, to $34.80, representing a loss of $35.40 per share, indicating severe market pessimism regarding the company's future prospects.
- Legal Consultation Opportunity: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact Kahn Swick & Foti for a free consultation, assisting them in navigating the lawsuit process.
See More
Corcept Therapeutics Faces Class Action Lawsuit for Securities Fraud
- Class Action Initiated: Pomerantz LLP has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by April 21, 2026.
- FDA Complete Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, requiring additional evidence of effectiveness, which poses significant compliance challenges for the company.
- Stock Price Plunge: Following the FDA's negative feedback, Corcept's stock price plummeted by $35.40, or 50.4%, closing at $34.80 per share on December 31, 2025, severely impacting investor confidence and market performance.
- Legal Firm Background: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, emphasizes its commitment to fighting for victims of securities fraud and corporate misconduct, highlighting the potential legal ramifications for Corcept in this case.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the support for its drug relacorilant's New Drug Application (NDA) to the FDA, despite the agency expressing concerns about the adequacy of clinical evidence, which exposed investors to significant risk of loss.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this legal domain.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging affected investors to submit their losses before this date to participate in the lawsuit.
- Loss Scope: The lawsuit pertains to investor losses incurred between October 31, 2024, and December 30, 2025, with allegations that the company failed to disclose critical communications with the FDA, leading to misleading expectations regarding the potential approval of its lead drug candidate, relacorilant.
- Information Asymmetry: The complaint alleges that Corcept's management was privately informed of potential failure in FDA communications but publicly conveyed an optimistic outlook to investors, creating a significant information gap that may have led to misguided investment decisions.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, aiming to enhance oversight and accountability for corporate misconduct.
See More
